Pharmabiotic Research Institute

What Pharmabiotic Research Institute does

Pharmabiotic Research Institute (PRI), legally IRP – Institut de Recherche Pharmabiotique, is a European non-for-profit association founded in 2010 and headquartered in Narbonne, France, with an additional office in Brussels, Belgium. It operates as the EU Microbiome Regulatory Science Expertise Center, supporting the development and registration of therapeutic and diagnostic products emerging from microbiome science. PRI is governed by French law of 1901 and is membership-funded; it does not engage in paid consulting or lobbying and is led by a board of directors drawn from its corporate members.

PRI's core offering is regulatory science expertise, not commercial products. It educates and federates industry, academic institutions, and EU regulatory representatives through collaborative pre-competitive Task Groups, peer-reviewed publications in journals including The Lancet Microbe and NPJ Biofilms Microbiomes, representation to EMA/EDQM and national competent authorities, and the annual Pharmabiotics Conference & Partnering Event. Its products and services are organized around five lines: the core regulatory science advisory service, the annual conference, Task Groups on topics such as OMICS standardization and analytical methods, peer-reviewed publications, and regulatory science tools covering quality, safety, and efficacy assessment methodologies.

Revenue comes from annual membership dues across three tiers (Active Industry Members focused on regulatory activities, Active Networking Members focused on R&D and networking, and Associate Members for academic/public research entities) plus conference registration. With 1–10 employees and no external investors or funding rounds, PRI operates a lean, association-based model whose value proposition rests on neutrality, EU regulatory access, and the convening power of its member network rather than scalable software or product economics.

Name

Pharmabiotic Research Institute

Legal name

IRP – Institut de Recherche Pharmabiotic / Pharmabiotic Research Institute (PRI)

Website

https://pharmabiotic.org

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Pharmabiotic Research Institute is a European non-profit association founded in 2010 that serves as the EU's microbiome regulatory science expertise center, supporting industry and academic developers of microbiome-based therapeutics and diagnostics through membership services, task groups, publications, and an annual conference.

Ownership category

akta.pro rank

Product category

Biotech Regulatory Affairs Services

NAICS

Other Scientific and Technical Consulting Services (54169), Colleges, Universities, and Professional Schools (611310)

SIC

Services-Membership Organizations (8600), Services-Educational Services (8200)

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

akta.pro secondary industry

Clinical Trials Authorization & Oversight (GCP) (HLAJADAF)

Keywords

• Microbiome regulatory science
• Regulatory affairs services
• Biotech association membership
• EU medicinal product guidance
• Microbiome therapeutics consulting

Headquarters

HQ city

Narbonne

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Membership Dues: Annual membership dues from Active Industry Members, Active Networking Members, and Associate Members. Payment of annual membership dues following signature of the membership contract confirms membership. Membership categories include 'Active Industry Members' interested in regulatory activities and 'Active Networking Members' interested in R&D activities.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Pharmabiotic Research Institute is a European non-profit association providing regulatory science expertise, collaborative platforms, and educational resources to support developers of microbiome-based therapeutic and diagnostic products in navigating EU regulatory frameworks for market authorization. The association offers membership-based access to task groups, peer-reviewed publications, annual conferences, and direct representation with EU regulatory bodies including EMA and EDQM.

Product overview

Pharmabiotic Research Institute (PRI) is a European non-profit association established in 2010, serving as the EU Microbiome Regulatory Science Expertise Center. Rather than a commercial product company, PRI offers a portfolio of regulatory science services including collaborative Task Groups addressing specific technical challenges, peer-reviewed publications on regulatory requirements, and the annual Pharmabiotics Conference & Partnering Event. The organization's core function is supporting developers of microbiome-based medicinal products through education, pre-competitive collaboration, and engagement with EU regulatory authorities to facilitate market authorization of therapeutic and diagnostic innovations.

Differentiator

Problem solved

Functional benefit

Products and services

• PRI Membership Program Membership subscription offering corporate entities and academic institutions access to PRI's regulatory science expertise, collaborative task groups, networking opportunities, and pre-competitive research platforms for microbiome-based medicinal products.
• Pharmabiotics Conference & Partnering Event Annual conference bringing together microbiome researchers, biotech companies, and product developers to discuss regulatory science, product development, and commercialization pathways.
• PRI Task Groups Collaborative working groups addressing specific regulatory science challenges in microbiome product development, including standardization, analytical methods, and OMICS technologies.
• PRI Peer-Reviewed Publications Peer-reviewed regulatory science publications developed collaboratively by PRI members addressing technical and scientific requirements for microbiome-based medicinal products in the EU market, published in journals including The Lancet Microbe, NPJ Biofilms Microbiomes, and Microbiome.
• Regulatory Science & Tools Expert guidance on applying regulatory science approaches for microbiome-based medicinal products, including quality, safety, and efficacy assessment methodologies, and navigating EU regulatory frameworks.

Quantifiable outcome

• Facilitated EU market access for microbiome-based medicinal products through regulatory science expertise

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core and minor.

• IPA EuropecoreStrategic or Co-development Partner · 1 June 2026Joint position paper submitted to European Commission and Substances of Human Origin Coordination Board (SCB) clarifying status of isolated microbial strains. Jointly provided supporting information and legal references to maintain isolated microbial strains outside scope of SoHO Regulation.
• I-Squared Communications LtdcoreStrategic or Co-development Partner · 1 January 2024Conference operations partner for annual Pharmabiotics Conference & Partnering Event. Led by Nick Gallo, provides expert execution and production of the annual conference.
• ISAPP (International Scientific Association for Probiotics and Prebiotics)minorStrategic or Co-development Partner · 1 January 2023Magali Cordaillat-Simmons participated as invited expert at ISAPP annual meeting in Denver, Colorado. Workshop discussion on regulatory science and differences between probiotic strains in medicinal products vs foods/supplements.
• Human Microbiome Action ConsortiumcoreStrategic or Co-development Partner · 1 January 2021EU-funded Horizon 2020 project (grant agreement N° 964590) coordinated by France's INRAE. PRI serves as a core partner co-leading Ethics & Regulatory transversal work package. Project aims to maximize impact of European microbiome research and create coherence in how microbiome research is performed. PRI coordinates Delphi survey on microbiome-based biomarkers.
• MEDICEN (Paris-based human health innovation cluster)minorStrategic or Co-development PartnerCollaborative working group on gut microbiome integration in drug discovery and development. Patrick Jimonet presented collaborative publication on drug-microbiota metabolism at Pharmabiotics 2024.
• NIBSC/MHRA (UK)minorStrategic or Co-development PartnerDr. Chrysi Sergaki presented on microbiome standardization efforts and development of reference reagents (DNA-Gut-mix RR, WC-Gut RR) for bias detection in microbiome analysis.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Regional players

• MedTech Europe: European trade association for the medical technology industry; comparable as a Brussels-based industry association engaged with EU regulatory frameworks, though focused on devices rather than microbiome therapeutics.
• EDQM (European Directorate for the Quality of Medicines & HealthCare): Council of Europe body that develops quality standards for medicines; comparable as the upstream EU regulator with whom PRI engages, and a potential alternative venue for microbiome standard-setting.

Broad incumbents

• BIO (Biotechnology Innovation Organization): Largest global biotech trade association with EU operations; comparable as a broader industry association that increasingly covers microbiome regulatory advocacy, representing a competitive umbrella for PRI's member base.
• DIA (Drug Information Association): Global life sciences professional association covering regulatory science, clinical development, and policy; comparable as an established forum for regulatory affairs professionals that overlaps with PRI's educational mission.
• EFPIA (European Federation of Pharmaceutical Industries and Associations): European pharmaceutical industry association; comparable as an influential EU policy/regulatory body that engages with EMA, potentially diluting PRI's voice on microbiome-specific issues.

Direct peers

• ISAPP (International Scientific Association for Probiotics and Prebiotics): Global scientific association for probiotics and prebiotics; directly comparable to PRI as a non-profit scientific association focused on microbiome-related science, with collaborative engagement with PRI and overlapping membership.
• Microbiome Therapeutics Innovation Group (MITIG): US-based coalition advocating for microbiome therapeutic developers; directly comparable to PRI as a microbiome therapeutics-focused industry group, but US-scoped rather than EU-scoped.
• IPA Europe (International Probiotics Association Europe): European trade association for the probiotic industry; co-author of PRI's 2026 joint position paper to the European Commission. Directly comparable as a microbiome-focused European membership association representing industry interests.

Emerging players

• Human Microbiome Action Consortium: EU-funded Horizon 2020 coordination project led by INRAE; PRI is a core partner co-leading Ethics & Regulatory work, making it a directly comparable emerging coordination effort that competes for EU microbiome influence.
• Global Microbiome Council: Industry coalition advancing policy and regulatory frameworks for microbiome-based products; comparable as a competing industry-led microbiome advocacy body with overlapping member companies.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/PRI_Microbiome
• LinkedInlinkedin.com/company/pharmabiotic-research-institute-pri

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmabiotic Research Institute